Molecular mechanisms in evolutionary cardiology failure

被引:19
|
作者
Swynghedauw, Bernard [1 ]
Delcayre, Claude
Samuel, Jane-Lyse
Mebazaa, Alexandre [2 ]
Cohen-Solal, Alain [1 ]
机构
[1] Hop Lariboisiere, INSERM, U942, Dept Cardiol, F-75475 Paris 10, France
[2] Hop Lariboisiere, Dept Anesthesiol, F-75475 Paris, France
来源
ANALYSIS OF CARDIAC DEVELOPMENT: FROM EMBRYO TO OLD AGE | 2010年 / 1188卷
关键词
heart failure; cardiac hypertrophy; microRNA; fibrosis; fetal hypothesis; wall stress hypothesis; Laplace's law; aldosterone; evolution; Darwinian or evolutionary medicine; GENE-EXPRESSION; CARDIAC-HYPERTROPHY; HEART-FAILURE; PRESSURE-OVERLOAD; PHENOTYPIC PLASTICITY; ALDOSTERONE; RAT; CARDIOMYOPATHY; TRANSCRIPTOME; MICROARRAY;
D O I
10.1111/j.1749-6632.2009.05084.x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Integration of the relevant evolutionary paradigm in cardiology has not yet been fully achieved: In the past, heart failure (HF) was mainly ascribed to infections, and the origins of cardiac hypertrophy (CH) were regarded as mechanical. Recent changes in lifestyle have both reduced the incidence of infections and increased lifespan, and H F is now seen as a complex disease one that is still caused by mechanical disorder, but also associated with ischemia and senescence. The long-held view that CH serves to restore myocardial economy back to normal is still valid. The adaptive process is characterized by a quantitative and a qualitative fetal gene reprogramming, which is now being confirmed by recent advances in microRNA research. It underscores the fact CH is the physiologic reaction of the heart to a pathologic stimulus. The goal for therapy is economic, not inotropic. Another major issue is myocardial fibrosis, a major determinant of diastolic function and arrhythmias. Recent changes in lifestyle have crucially modified the context in which HF occurs.
引用
收藏
页码:58 / 67
页数:10
相关论文
共 50 条
  • [41] Molecular mechanisms and evolutionary history of phytomelatonin in flowering
    Mou, Zongmin
    Wang, Houping
    Chen, Suiyun
    Reiter, Russel J.
    Zhao, Dake
    JOURNAL OF EXPERIMENTAL BOTANY, 2022, 73 (17) : 5840 - 5850
  • [42] Protective Role of Polyphenols in Heart Failure: Molecular Targets and Cellular Mechanisms Underlying Their Therapeutic Potential
    Najjar, Rami S.
    Feresin, Rafaela G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (04) : 1 - 26
  • [43] Mineralocorticoid receptors in pulmonary hypertension and right heart failure: From molecular biology to therapeutic targeting
    Mamazhakypov, Argen
    Hein, Lutz
    Lother, Achim
    PHARMACOLOGY & THERAPEUTICS, 2022, 231
  • [44] DIABETES MELLITUS AND HEART FAILURE - A MODERN LOOK AT THE MECHANISMS OF DEVELOPMENT
    Svarovskaya, Alla, V
    Garganeeva, Alla A.
    DIABETES MELLITUS, 2022, 25 (03): : 267 - 274
  • [45] Update for 2014 on Clinical Cardiology, Geriatric Cardiology, and Heart Failure and Transplantation
    Baron-Esquivias, Gonzalo
    Manito, Nicolas
    Lopez Diaz, Javier
    Martin Santana, Antonio
    Garcia Pinilla, Jose Manuel
    Gomez Doblas, Juan Jose
    Gomez Bueno, Manuel
    Barrios Alonso, Vivencio
    Luis Lamberth, Jose
    REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (04): : 317 - 323
  • [46] Emerging mechanisms of T-tubule remodelling in heart failure
    Guo, Ang
    Zhang, Caimei
    Wei, Sheng
    Chen, Biyi
    Song, Long-Sheng
    CARDIOVASCULAR RESEARCH, 2013, 98 (02) : 204 - 215
  • [47] Molecular Mechanisms of Diaphragm Myopathy in Humans With Severe Heart Failure
    Mangner, Norman
    Garbade, Jens
    Heyne, Estelle
    van den Berg, Marloes
    Winzer, Ephraim B.
    Hommel, Jennifer
    Sandri, Marcus
    Jozwiak-Nozdrzykowska, Joanna
    Meyer, Anna L.
    Lehmann, Sven
    Schmitz, Clara
    Malfatti, Edoardo
    Schwarzer, Michael
    Ottenheijm, Coen A. C.
    Bowen, T. Scott
    Linke, Axel
    Adams, Volker
    CIRCULATION RESEARCH, 2021, 128 (06) : 706 - 719
  • [48] Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)
    de Boer, Rudolf A.
    Heymans, Stephane
    Backs, Johannes
    Carrier, Lucie
    Coats, Andrew J. S.
    Dimmeler, Stefanie
    Eschenhagen, Thomas
    Filippatos, Gerasimos
    Gepstein, Lior
    Hulot, Jean-Sebastien
    Knoll, Ralph
    Kupatt, Christian
    Linke, Wolfgang A.
    Seidman, Christine E.
    Tocchetti, C. Gabriele
    van der Velden, Jolanda
    Walsh, Roddy
    Seferovic, Petar M.
    Thum, Thomas
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (03) : 406 - 420
  • [49] Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
    Cheng, Hui
    Force, Thomas
    CIRCULATION RESEARCH, 2010, 106 (01) : 21 - 34
  • [50] Molecular Mechanisms That Differentiate Apoptosis from Programmed Necrosis
    Dorn, Gerald W., II
    TOXICOLOGIC PATHOLOGY, 2013, 41 (02) : 227 - 234